IMC Chicago
TEVA icon

IMC Chicago’s Teva Pharmaceuticals TEVA Stock Holding History

IMC Chicago’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.23M Sell
273,100
-437,700
-62% -$14.1M ﹤0.01% 1427
2025
Q4 		$22.2M Buy
710,800
+205,200
+41% +$5.06M 0.01% 798
2025
Q3 		$10.2M Sell
505,600
-41,600
-8% -$731K ﹤0.01% 1136
2025
Q2 		$9.17M Buy
547,200
+143,100
+35% +$2.31M ﹤0.01% 1054
2025
Q1 		$6.21M Sell
404,100
-467,700
-54% -$8.35M ﹤0.01% 1118
2024
Q4 		$19.2M Buy
871,800
+445,500
+105% +$8.1M 0.01% 619
2024
Q3 		$7.68M Buy
426,300
+100
+0% +$1.75K ﹤0.01% 940
2024
Q2 		$6.93M Buy
426,200
+112,800
+36% +$1.74M ﹤0.01% 922
2024
Q1 		$4.42M Sell
313,400
-52,400
-14% -$661K ﹤0.01% 1010
2023
Q4 		$3.82M Buy
365,800
+41,900
+13% +$391K ﹤0.01% 969
2023
Q3 		$3.3M Buy
323,900
+145,000
+81% +$1.35M ﹤0.01% 843
2023
Q2 		$1.35M Sell
178,900
-301,300
-63% -$2.44M ﹤0.01% 981
2023
Q1 		$4.25M Buy
480,200
+149,500
+45% +$1.48M 0.01% 671
2022
Q4 		$3.02M Sell
330,700
-46,700
-12% -$407K ﹤0.01% 722
2022
Q3 		$3.05M Sell
377,400
-160,500
-30% -$1.42M ﹤0.01% 666
2022
Q2 		$4.04M Buy
537,900
+98,400
+22% +$857K 0.01% 581
2022
Q1 		$4.13M Sell
439,500
-104,000
-19% -$868K ﹤0.01% 595
2021
Q4 		$4.35M Buy
543,500
+178,500
+49% +$1.61M ﹤0.01% 647
2021
Q3 		$3.56M Buy
365,000
+8,600
+2% +$80.5K ﹤0.01% 698
2021
Q2 		$3.53M Buy
356,400
+54,400
+18% +$576K ﹤0.01% 654
2021
Q1 		$3.48M Buy
302,000
+45,700
+18% +$524K 0.01% 638
2020
Q4 		$2.47M Buy
256,300
+87,700
+52% +$840K ﹤0.01% 692
2020
Q3 		$1.52M Sell
168,600
-22,600
-12% -$239K ﹤0.01% 642
2020
Q2 		$2.36M Sell
191,200
-143,100
-43% -$1.62M ﹤0.01% 523
2020
Q1 		$3M Buy
334,300
+114,600
+52% +$1.17M 0.01% 421
2019
Q4 		$2.15M Sell
219,700
-54,300
-20% -$485K 0.01% 508
2019
Q3 		$1.89M Buy
274,000
+45,100
+20% +$346K 0.01% 467
2019
Q2 		$2.11M Buy
228,900
+124,400
+119% +$1.5M 0.01% 410
2019
Q1 		$1.64M Sell
104,500
-7,000
-6% -$123K 0.01% 400
2018
Q4 		$1.72M Buy
+111,500
New +$2.29M 0.01% 366

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IMC Chicago's TEVA Position: Q1 2026 in Review

IMC Chicago opened a new position in Teva Pharmaceuticals (TEVA) in Q1 2026: 89,569 shares worth $2.7M. The stake represents ﹤0.01% of the portfolio and ranks #2308 among its holdings. This is a return to the name: IMC Chicago previously reported a position in TEVA as recently as Q2 2025.

IMC Chicago first reported a position in TEVA in Q1 2019 and has held it in 18 quarters since. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • IMC Chicago held 89,569 shares of Teva Pharmaceuticals worth $2.7M as of Q1 2026.
  • Teva Pharmaceuticals was a new IMC Chicago position in Q1 2026.
  • Teva Pharmaceuticals made up ﹤0.01% of IMC Chicago's portfolio in Q1 2026, its #2308 holding.
  • IMC Chicago first reported a position in Teva Pharmaceuticals in Q1 2019 and has held it in 18 quarters since.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on IMC Chicago's 13F filing for Q1 2026, filed 5 May 2026.